In all CML cells, TKIs increased the SCD when combined with 8-Cl-Ado (from 20–39% (without TKI) to 45–68% (with imatinib), 51–73% (with dasatinib), 56–83% (with nilotinib), and 59–77% (with asciminib), Fig. 2c). Here, SCD is linked to chronic myelogenous leukemia, BCR-ABL1 positive.